secwatch.observer — SEC 8-K summary
======================================

Issuer:     HYPERION DEFI, INC. (HYPD)
CIK:        0001682639
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001104659-24-116782
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eyenovia Q3 2024 net loss $7.9M; advances MicroPine Phase 3 and launches clobetasol
--------------------------------------------------------------------------------

- Net loss of $7.9M ($0.11/share) vs $7.3M ($0.18/share) in Q3 2023; SG&A up 27% to $3.7M.
- Cash & equivalents $7.2M at Sept 30, 2024; evaluating long-term financing options.
- Phase 3 CHAPERONE (MicroPine) interim analysis planned this quarter; myopia market >$3B annually.
- U.S. launch of clobetasol propionate 0.05% for post-surgical ocular inflammation/pain.
- Mydcombi shipped to 230 new offices since April; appointed Andrew Jones as CFO; raised $10.7M net.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924116782/0001104659-24-116782-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1682639/000110465924116782/tm2428070d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-116782

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer